Novelix PharmaceuticalsBOM:536565 -0.80%68 EBITDA Margin % is 5.08% as of Mar. 2026, which is 327% above its 10-year median of 1.19. GuruFocus rates BOM:536565 with a GF Score™ of 68/100 and a GF Value™ of ₹144.17 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 117 Medical Distribution companies, Novelix Pharmaceuticals ranks worse than 66.67% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Novelix Pharmaceuticals EBITDA Margin % Related Terms
Novelix Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:536565 vs MCK, CAH, COR: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Novelix Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novelix Pharmaceuticals EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Novelix Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Novelix Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelix Pharmaceuticals (BOM:536565) has a EBITDA Margin % of 5.08% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novelix Pharmaceuticals and its competitors. This is 327% above median its historical median of 1.19. According to the industry distribution chart, Novelix Pharmaceuticals ranks #78 out of 117 companies in the Medical Distribution industry, placing it in the top 66.7%.
Is Novelix Pharmaceuticals' EBITDA Margin % too high?
Novelix Pharmaceuticals' current EBITDA Margin % of 5.08% is 327% above median its 10-year median of 1.19. The Medical Distribution industry median EBITDA Margin % is 4.28. Novelix Pharmaceuticals' value of 5.08% is 18.7% above this industry median. Based on the distribution chart, Novelix Pharmaceuticals ranks #78 out of 117 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Novelix Pharmaceuticals has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Novelix Pharmaceuticals' EBITDA Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Novelix Pharmaceuticals ranks #78 out of 117 companies for EBITDA Margin %. This places Novelix Pharmaceuticals in the lower half of its industry. The industry median EBITDA Margin % is 4.28. Novelix Pharmaceuticals' value of 5.08% is 18.7% above this benchmark. While the company's 10-year median is 1.19 vs. the industry median of 4.28, Novelix Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.28, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novelix Pharmaceuticals's current EBITDA Margin % of 5.08% is 18.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Novelix Pharmaceuticals and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novelix Pharmaceuticals's current EBITDA Margin % is 5.08%, which is 327% above median its own 10-year median of 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novelix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Novelix Pharmaceuticals (BOM:536565) is currently considered Possible Value Trap. The stock's GF Value™ is ₹144.17, compared to a current price of ₹77.97 — trading 45.9% below its estimated fair value. The current EBITDA Margin % is 5.08%, which is 327% above median its 10-year median of 1.19 and 18.7% above the Medical Distribution industry median of 4.28. Novelix Pharmaceuticals' overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Novelix Pharmaceuticals (BOM:536565), the current EBITDA Margin % is 5.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novelix Pharmaceuticals (BOM:536565) Overvalued in 2026?
Based on GuruFocus' analysis, Novelix Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹77.97 is trading 45.9% below its estimated GF Value™ of ₹144.17.
GuruFocus considers Novelix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for BOM:536565:
EBITDA Margin %: 5.08% (327% above median its 10-year median of 1.19)
GF Value™: ₹144.17 vs. price of ₹77.97 (45.9% below fair value)
Industry Position: 18.7% above the Medical Distribution median (#78 of 117)
No single metric tells the full story. See the BOM:536565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novelix Pharmaceuticals Ltd is into the business of Trading of Pharmaceuticals and related products and is into the business of trading of shares and securities. The company generates majaority of its revenue from the Pharmaceuticals business.
68GF Score
Get the complete analysis for BOM:536565
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:536565 has been successfully added to your 
